(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a Selective and Orally Active Inhibitor of Tumor Necrosis Factor-α Convertase

• Published in: The Journal of pharmacology and experimental therapeutics 2002-07, Vol.302 (1), p.390
• Main Authors: G. Beck, G. Bottomley, D. Bradshaw, M. Brewster, M. Broadhurst, R. Devos, C. Hill, W. Johnson, H.-J. Kim, S. Kirtland, J. Kneer, N. Lad, R. Mackenzie, R. Martin, J. Nixon, G. Price, A. Rodwell, F. Rose, J.-P. Tang, D. S. Walter, K. Wilson, E. Worth
• Format: Article
• Language: English
• ISSN: 0022-3565; 1521-0103
• DOI: 10.1124/jpet.302.1.390

Tumor necrosis factor-α (TNF-α), a cytokine secreted by inflammatory cells, has been implicated in several inflammatory disease states. ( E )-2( R )-[1( S )-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), is a potent, orally active inhibitor of the TNF-α convertase (TACE), an enzyme responsible for proteolytic cleavage of the membrane bound precursor, pro-TNF-α. Ro 32-7315 inhibited a recombinant form of TACE (IC 50 = 5.2 nM) with selectivity over related matrix metalloproteinases. In a cellular assay system, THP-1 cell line, and in human and rat whole blood, Ro 32-7315 significantly reduced lipopolysaccharide (LPS)-induced TNF-α release with IC 50 values of 350 ± 14 nM ( n = 5), 2.4 ± 0.5 μM ( n = 5), and 110 ± 18 nM ( n = 5), respectively. Oral administration of Ro 32-7315 to Wistar rats caused a dose-dependent inhibition of LPS-induced release of systemic TNF-α with an ED 50 of 25 mg/kg. Treatment (days 0–14) of Allen and Hamburys hooded rats with Ro 32-7315 (2.5, 5, 10, and 20 mg/kg, i.p., twice daily) significantly reduced adjuvant-induced secondary paw swelling (42, 71, 83, and 93%, respectively) as compared with the vehicle group. In the Ro 32-7315-treated group, the reduced paw swelling was associated with improved lesion score and joint mobility. Furthermore, in a placebo-controlled, single-dose study, Ro 32-7315 given orally (450 mg) significantly suppressed ex vivo, LPS-induced TNF-α release in the whole-blood samples taken from healthy male and female volunteers (mean inhibition of 42% over a 4-h duration, n = 6). These data collectively support the potential use of such a compound for the oral treatment of inflammatory disorders.